About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Anti-HIV Drugs Market Size, Top Share, Forecast to 2032
Anti-HIV Drugs Market

Anti-HIV Drugs Market Size, Share & Trends Analysis Report By Medication Class (Multi-class combination drugs, Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), HIV integrase strand transfer inhibitors), By Distribution Channel (Hospital pharmacies, Retail pharmacies, E-commerce) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI790DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Anti-HIV Drugs Market Introduction
    2. By Medication Class
      1. Introduction
        1. Medication Class By Value
      2. Multi-class combination drugs
        1. By Value
      3. Nucleoside reverse transcriptase inhibitors (NRTIs)
        1. By Value
      4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        1. By Value
      5. HIV integrase strand transfer inhibitors
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital pharmacies
        1. By Value
      3. Retail pharmacies
        1. By Value
      4. E-commerce
        1. By Value
    1. Introduction
    2. By Medication Class
      1. Introduction
        1. Medication Class By Value
      2. Multi-class combination drugs
        1. By Value
      3. Nucleoside reverse transcriptase inhibitors (NRTIs)
        1. By Value
      4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        1. By Value
      5. HIV integrase strand transfer inhibitors
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital pharmacies
        1. By Value
      3. Retail pharmacies
        1. By Value
      4. E-commerce
        1. By Value
    4. U.S.
      1. By Medication Class
        1. Introduction
          1. Medication Class By Value
        2. Multi-class combination drugs
          1. By Value
        3. Nucleoside reverse transcriptase inhibitors (NRTIs)
          1. By Value
        4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          1. By Value
        5. HIV integrase strand transfer inhibitors
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital pharmacies
          1. By Value
        3. Retail pharmacies
          1. By Value
        4. E-commerce
          1. By Value
    5. Canada
    1. Introduction
    2. By Medication Class
      1. Introduction
        1. Medication Class By Value
      2. Multi-class combination drugs
        1. By Value
      3. Nucleoside reverse transcriptase inhibitors (NRTIs)
        1. By Value
      4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        1. By Value
      5. HIV integrase strand transfer inhibitors
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital pharmacies
        1. By Value
      3. Retail pharmacies
        1. By Value
      4. E-commerce
        1. By Value
    4. U.K.
      1. By Medication Class
        1. Introduction
          1. Medication Class By Value
        2. Multi-class combination drugs
          1. By Value
        3. Nucleoside reverse transcriptase inhibitors (NRTIs)
          1. By Value
        4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          1. By Value
        5. HIV integrase strand transfer inhibitors
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital pharmacies
          1. By Value
        3. Retail pharmacies
          1. By Value
        4. E-commerce
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Medication Class
      1. Introduction
        1. Medication Class By Value
      2. Multi-class combination drugs
        1. By Value
      3. Nucleoside reverse transcriptase inhibitors (NRTIs)
        1. By Value
      4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        1. By Value
      5. HIV integrase strand transfer inhibitors
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital pharmacies
        1. By Value
      3. Retail pharmacies
        1. By Value
      4. E-commerce
        1. By Value
    4. China
      1. By Medication Class
        1. Introduction
          1. Medication Class By Value
        2. Multi-class combination drugs
          1. By Value
        3. Nucleoside reverse transcriptase inhibitors (NRTIs)
          1. By Value
        4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          1. By Value
        5. HIV integrase strand transfer inhibitors
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital pharmacies
          1. By Value
        3. Retail pharmacies
          1. By Value
        4. E-commerce
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Medication Class
      1. Introduction
        1. Medication Class By Value
      2. Multi-class combination drugs
        1. By Value
      3. Nucleoside reverse transcriptase inhibitors (NRTIs)
        1. By Value
      4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        1. By Value
      5. HIV integrase strand transfer inhibitors
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital pharmacies
        1. By Value
      3. Retail pharmacies
        1. By Value
      4. E-commerce
        1. By Value
    4. UAE
      1. By Medication Class
        1. Introduction
          1. Medication Class By Value
        2. Multi-class combination drugs
          1. By Value
        3. Nucleoside reverse transcriptase inhibitors (NRTIs)
          1. By Value
        4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          1. By Value
        5. HIV integrase strand transfer inhibitors
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital pharmacies
          1. By Value
        3. Retail pharmacies
          1. By Value
        4. E-commerce
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Medication Class
      1. Introduction
        1. Medication Class By Value
      2. Multi-class combination drugs
        1. By Value
      3. Nucleoside reverse transcriptase inhibitors (NRTIs)
        1. By Value
      4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        1. By Value
      5. HIV integrase strand transfer inhibitors
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital pharmacies
        1. By Value
      3. Retail pharmacies
        1. By Value
      4. E-commerce
        1. By Value
    4. Brazil
      1. By Medication Class
        1. Introduction
          1. Medication Class By Value
        2. Multi-class combination drugs
          1. By Value
        3. Nucleoside reverse transcriptase inhibitors (NRTIs)
          1. By Value
        4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          1. By Value
        5. HIV integrase strand transfer inhibitors
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital pharmacies
          1. By Value
        3. Retail pharmacies
          1. By Value
        4. E-commerce
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Anti-HIV Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Gilead Sciences IncSciences, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. ViiV Healthcare
    3. Merck & Co., Inc.
    4. AbbVie
    5. Hoffmann-La Roche Ltd.
    6. Teva Pharmaceutical Industries Ltd.
    7. Bristol-Myers Squibb
    8. Pfizer
    9. Shionogi
    10. Cipla Limited
    11. Boehringer Ingelheim International GmbH
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Bispecific Antibodies Market Size The global bispecific antibodies market size was valued at USD 11.84 billion in 2024 and is expected to grow from USD 17.10 billion in 2025 to USD 323.21 billion by 2033, growing at a CAGR of 44.4% du
Buy Now
Global Report
X-Ray Inspection System Market Size The global x-ray inspection system market size was valued at USD 834.65 million in 2024 and is expected to grow from USD 889.74 million in 2025 to reach USD 1483.61 million by 2033, growin
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.